Mirpharm

Mirpharm is a bridge between best practices and innovations on the one hand, and with doctors and patients on the other.

Mirpharm today

Mirpharm is an international group of companies with its own R&D centers and manufacture in Russia and European Union.
We realize full-cycle pharmaceutical development projects in Russia and abroad, from the development of substance synthesis technologies to the market launch of the finished product.

  • 20 years Ongoing development
  • 20+ tons Pharmaceutical substances per year
  • 7+ million Packs of drug products per year
  • 100+  Drug products in terms of development and registration
  • 400+  Employees

Values

  • Honesty and transparency

    We do our business openly and honestly. Honesty is not just a word for us - it is the only way of thinking and acting. Honesty and transparency in relations between employees serves as the basis for building relationships with patients, doctors and business partners.

  • Responsibility

    Engaged in the production of drug products, companies should not cause any harm with their production activities both to the surrounding people and the ecology of our common home - our planet.

  • Expert level

    In today's competitive world, to be successful in business and useful to others, it is necessary to maintain an expert level of competencies and go ahead with development.

  • Trust

    Trust cannot be won once and for ever. In order to be trusted, you should constantly make an effort and never fail those who trust you. We are proud of the multiannual trust of doctors and highly appreciate the trust of colleagues and business partners.

We manufacture drug products in the following therapeutic areas

Read more about our products

Scope of activities

  • Development and registration of pharmaceutical substances and finished drug products.

  • Manufacture of pharmaceutical substances of any complexity and finished drug products.

  • Promotion of modern methods of therapy. We make it accessible to patients.

  • Provision of unique drug products. We specialize in drug products unique to the Russian market.

Company History

The synthesis of pharmaceutical substances is a determining factor in the quality of drug products

  • 1999

    Year of foundation of the first company of the future Mirpharm group.

  • 2001

    Start of manufacture

    In the first science city of Russia - Obninsk, Kaluga Region, on the territory of the experimental sector of the Medical Radiological Scientific Center (MRSC RAMS), the production part of the Mirpharm group was founded - Obninsk Chemical and Pharmaceutical Company CJSC (OCPC CJSC). It was the first chemical and pharmaceutical production in the Kaluga region. The main focus was the production of active pharmaceutical ingredients (API)

  • 2002

    Manufacturing license obtained

    From the foundation day to the present day, the company has been developing and carrying out industrial chemical synthesis of active pharmaceutical ingredients (API). Industrial manufacture started with the release of the pharmaceutical substance Diazolin. This substance was a part of a large number of anti-allergic agents, which were produced by Russian enterprises from imported substances. Commercial distribution of the high-quality Russian substance was relevant, competitive and absolutely successful. This gave the company the opportunity to continue its development.

  • 2003

    New workshop

    A workshop was founded for the production of solid finished drug products (tablets, pellets and capsules). The reconstruction of the plant was carried out in accordance with the requirements of good manufacturing practice (GMP). The workshop is equipped with modern equipment (manufactured by the Italian company IMA and the German company GLATT) and the most modern quality control devices.

  • 2008

    Major partner

    The sale of successful brands created by the company: Mexiprim, Ginepriston®, Ginestril®, Miropriston®, Mirolut® became a source of investment in the following developments of substances and finished drug products. Later, another drug product created by the company and successfully marketed with the trade name Tranexam® was sold. Transactions made by the company became the beginning for long-term mutually beneficial cooperation with the company Nizhpharm JSC (STADA CIS). OCPC CJSC remains the only manufacturer of these drug products.

  • 2011-2013

    Window to Europe

    Mirpharm is developing its own research and production facilities in the European Union.

  • 2012

    The first victory

    OCPC CJSC was inspected by the state service of Ukraine. The company, among the first ones in Russia, was issued the GMP certificate of Ukraine, which allows deliveries of manufactured products to the territory of Ukraine. In the same year, the Mirpharm production unit OCPC CJSC was first awarded the TechUp Award (TOP-30).

  • 2017

    The beginning of the orphan direction development

    In February 2018, the drug product Mitotan (INN) was registered - an antitumor agent that is used for the symptomatic treatment of patients with a progressive (inoperable, metastatic or recurring) form of cancer of the adrenal cortex, which is a rare (orphan) disease.

    Learn more

  • 2022

    New medicines

    5 modern medicines for the treatment of orphan diseases have been successfully registered, 3 of which have been registered in Russia and the EAEU for the first time. There are 3 more products in various stages of registration

  • Onwards and upwards

    We continue our development

Manufacture

Obninsk Chemical and Pharmaceutical Company CJSC is a modern production site in the first science city of Russia - the city of Obninsk, Kaluga Region. The company is consistently implementing a policy aimed at creating an efficient and safe production, maintaining high quality standards of manufactured drug products, using the capabilities of modern technologies. Production departments of the company are equipped with modern equipment of European production.

Manufacture details

Please read our privacy policy